The hormone acts simultaneously on the brain (satiety), pancreas (insulin release, glucagon suppression), and stomach (slowed emptying)
showed a dose-dependent reduction in food intake with GLP-1 infusion in 16 healthy male subjects [9]
The safety and pharmacodynamic results in the multiple-dose trial must be interpreted in light of the high dose levels (2040 mg oral semaglutide) and the relatively fast initial dose escalation in this trial compared with the phase III trials, where dose levels of 314 mg oral semaglutide are investigated and a slower initial dose escalation is used to minimise gastrointestinal adverse effects
Treatment is typically initiated within specialist weight management services for adults meeting specific BMI and comorbidity criteria, with ongoing monitoring and continuation requirements
The best time to plan your exit strategy is at the very beginning
Using the Naranjo scale, 33 cases (84.6%) were deemed to have a probable causal relationship between GLP-1 RAs and AP, while 4 cases (10.3%) were classified as possible